Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator

Fig. 2

Glucose (panel A), fatty acids (panel C), β-OH butyrate (panel E) and insulin (panel G) plasma concentrations before (PE and PI) and during treatments (E and I). Change in metabolite concentrations (panels B, D, F, H) between treatments (ΔT) or between treatment and washout (ΔE and ΔI). Data are Mean ± SEM. *p < 0.05; **p < 0.01

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840